125 related articles for article (PubMed ID: 35650084)
1. [Analysis of Factors Affecting Proteinuria Onset Timing in Patients Treated with Bevacizumab].
Murakami A; Noto K; Ota R; Hirata A
Yakugaku Zasshi; 2022; 142(6):641-649. PubMed ID: 35650084
[TBL] [Abstract][Full Text] [Related]
2. Proteinuria frequency and subsequent renal dysfunction in bevacizumab-treated patients: a single center, retrospective, observational study.
Kataoka S; Nishikawa Y; Funakoshi T; Horimatsu T; Sakuragi M; Uchino E; Hiragi S; Yamamoto S; Sakai K; Matsubara T; Yanagita M; Muto M
Int J Clin Oncol; 2024 Apr; 29(4):398-406. PubMed ID: 38351273
[TBL] [Abstract][Full Text] [Related]
3. Hypertension and Proteinuria as Predictive Factors of Effects of Bevacizumab on Advanced Breast Cancer in Japan.
Tanaka H; Takahashi K; Yamaguchi K; Kontani K; Motoki T; Asakura M; Kosaka S; Yokomise H; Houchi H
Biol Pharm Bull; 2018; 41(4):644-648. PubMed ID: 29607938
[TBL] [Abstract][Full Text] [Related]
4. Predictive factors for the development of proteinuria in cancer patients treated with bevacizumab, ramucirumab, and aflibercept: a single-institution retrospective analysis.
Kanbayashi Y; Ishikawa T; Tabuchi Y; Sakaguchi K; Ouchi Y; Otsuji E; Takayama K; Taguchi T
Sci Rep; 2020 Feb; 10(1):2011. PubMed ID: 32029849
[TBL] [Abstract][Full Text] [Related]
5. Risks of proteinuria and hypertension with bevacizumab, an antibody against vascular endothelial growth factor: systematic review and meta-analysis.
Zhu X; Wu S; Dahut WL; Parikh CR
Am J Kidney Dis; 2007 Feb; 49(2):186-93. PubMed ID: 17261421
[TBL] [Abstract][Full Text] [Related]
6. Long-term toxicity of bevacizumab therapy in neurofibromatosis 2 patients.
Slusarz KM; Merker VL; Muzikansky A; Francis SA; Plotkin SR
Cancer Chemother Pharmacol; 2014 Jun; 73(6):1197-204. PubMed ID: 24710627
[TBL] [Abstract][Full Text] [Related]
7. Bevacizumab increases risk for severe proteinuria in cancer patients.
Wu S; Kim C; Baer L; Zhu X
J Am Soc Nephrol; 2010 Aug; 21(8):1381-9. PubMed ID: 20538785
[TBL] [Abstract][Full Text] [Related]
8. Incidence and relevance of proteinuria in bevacizumab-treated patients: pooled analysis from randomized controlled trials.
Lafayette RA; McCall B; Li N; Chu L; Werner P; Das A; Glassock R
Am J Nephrol; 2014; 40(1):75-83. PubMed ID: 25059491
[TBL] [Abstract][Full Text] [Related]
9. Antiproteinuric effects of renin-angiotensin inhibitors in lung cancer patients receiving bevacizumab.
Nihei S; Sato J; Harada T; Kuyama S; Suzuki T; Waga N; Saito Y; Kisara S; Yokota A; Okada K; Tsuchiya M; Terui K; Tadokoro Y; Chiba T; Kudo K; Oizumi S; Inoue A; Morikawa N
Cancer Chemother Pharmacol; 2018 Jun; 81(6):1051-1059. PubMed ID: 29651572
[TBL] [Abstract][Full Text] [Related]
10. Clinical utility of routine proteinuria evaluation in treatment decisions of patients receiving bevacizumab for metastatic solid tumors.
Yeh J; Frieze D; Martins R; Carr L
Ann Pharmacother; 2010 Jun; 44(6):1010-5. PubMed ID: 20460557
[TBL] [Abstract][Full Text] [Related]
11. Safety of bevacizumab treatment in combination with standard chemotherapy for metastatic colorectal cancer: a retrospective review of 65 Japanese patients.
Tamiya A; Yamazaki K; Boku N; Machida N; Kojima T; Taku K; Yasui H; Fukutomi A; Hironaka S; Onozawa Y
Int J Clin Oncol; 2009 Dec; 14(6):513-7. PubMed ID: 19967487
[TBL] [Abstract][Full Text] [Related]
12. Clinicopathological spectrum of kidney diseases in cancer patients treated with vascular endothelial growth factor inhibitors: a report of 5 cases and review of literature.
Usui J; Glezerman IG; Salvatore SP; Chandran CB; Flombaum CD; Seshan SV
Hum Pathol; 2014 Sep; 45(9):1918-27. PubMed ID: 25087655
[TBL] [Abstract][Full Text] [Related]
13. Deferred use of bevacizumab for recurrent glioblastoma is not associated with diminished efficacy.
Piccioni DE; Selfridge J; Mody RR; Chowdhury R; Li S; Lalezari S; Wawrzynski J; Quan J; Zurayk M; Chou AP; Sanchez DE; Liau LM; Ellingson BM; Pope WB; Nghiemphu PL; Green RM; Wang HJ; Yong WH; Elashoff R; Cloughesy TF; Lai A
Neuro Oncol; 2014 Jun; 16(6):815-22. PubMed ID: 24627236
[TBL] [Abstract][Full Text] [Related]
14. Urinary podocyte excretion and proteinuria in patients treated with antivascular endothelial growth factor therapy for solid tumor malignancies.
Hayman SR; Calle JC; Jatoi A; Craici IM; Wagner SJ; Weaver AL; Greene EL; Grande JP; Garovic VD
Oncology; 2014; 86(5-6):271-8. PubMed ID: 24902997
[TBL] [Abstract][Full Text] [Related]
15. Overview of bevacizumab: a new cancer therapeutic strategy targeting vascular endothelial growth factor.
Ignoffo RJ
Am J Health Syst Pharm; 2004 Nov; 61(21 Suppl 5):S21-6. PubMed ID: 15552623
[TBL] [Abstract][Full Text] [Related]
16. Renin-angiotensin system inhibitors for countering proteinuria induced by angiogenesis inhibitors: a retrospective observational analysis.
Hirai T; Shuji Y; Takiyama M; Hanada K; Itoh T
Cancer Chemother Pharmacol; 2019 Jul; 84(1):195-202. PubMed ID: 31119376
[TBL] [Abstract][Full Text] [Related]
17. [Bevacizumab and arterial hypertension or proteinuria: management].
Senellart H; Bennouna J
Rev Mal Respir; 2008 Jun; 25(6):767-72. PubMed ID: 18772832
[TBL] [Abstract][Full Text] [Related]
18. Phase I trial and pharmacokinetic study of bevacizumab in pediatric patients with refractory solid tumors: a Children's Oncology Group Study.
Glade Bender JL; Adamson PC; Reid JM; Xu L; Baruchel S; Shaked Y; Kerbel RS; Cooney-Qualter EM; Stempak D; Chen HX; Nelson MD; Krailo MD; Ingle AM; Blaney SM; Kandel JJ; Yamashiro DJ;
J Clin Oncol; 2008 Jan; 26(3):399-405. PubMed ID: 18202416
[TBL] [Abstract][Full Text] [Related]
19. Immunoglobulin A nephropathy with massive paramesangial deposits caused by anti-vascular endothelial growth factor therapy for metastatic rectal cancer: a case report and review of the literature.
Yahata M; Nakaya I; Sakuma T; Sato H; Aoki S; Soma J
BMC Res Notes; 2013 Nov; 6():450. PubMed ID: 24207130
[TBL] [Abstract][Full Text] [Related]
20. Assessment of extended urine protein monitoring frequency in patients receiving bevacizumab.
Schiffer M; Zukovic L; Hall S; Merl MY
J Oncol Pharm Pract; 2021 Jun; 27(4):902-906. PubMed ID: 32715917
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
